• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer.

作者信息

Margosiak S A, Vanderpool D L, Sisson W, Pinko C, Kan C C

机构信息

Department of Biophysics, Agouron Pharmaceuticals, Inc., La Jolla, California 92037, USA.

出版信息

Biochemistry. 1996 Apr 23;35(16):5300-7. doi: 10.1021/bi952842u.

DOI:10.1021/bi952842u
PMID:8611517
Abstract

The single-chain 28 kDa human cytomegalovirus (HCMV) protease catalytic domain containing the A143Q mutation has been kinetically and conformationally characterized. The specific activity of the HCMV A143Q protease (HCMVp) increases as the protease concentration increases, suggesting that this protease oligomerizes at high protein concentration to form a more active species. Both cross-linking and light-scattering studies of HCMVp show the existence of a homodimer with an apparent molecular mass of 56 kDa under low ionic strength and high protein concentration. The cosolvent and solute effects of glycerol, trisodium citrate, and NaCl as well as the temperature effects on the HCMVp activity and quaternary structure were investigated. The effects induced by cosolvents and temperature can largely be explained by their influences in the dimerization or oligomerization state of HCMVp. The dissociation constant (Kd) for the HCMVp homodimer was determined to be 8 +/- 1 microM with all activity attributed to the dimeric form. Monomeric HCMVp is inactive. This report demonstrates that in vitro, HCMV A143Q protease exists as an obligate catalytic homodimer. This protease dimerization may have regulatory significance during viral replication.

摘要

相似文献

1
Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer.
Biochemistry. 1996 Apr 23;35(16):5300-7. doi: 10.1021/bi952842u.
2
Investigation of the induced-fit mechanism and catalytic activity of the human cytomegalovirus protease homodimer via molecular dynamics simulations.
Proteins. 2003 Sep 1;52(4):483-91. doi: 10.1002/prot.10403.
3
Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease.二聚化调节人巨细胞病毒蛋白酶催化活性的分子机制。
Nat Struct Biol. 2001 Sep;8(9):810-7. doi: 10.1038/nsb0901-810.
4
Three-dimensional structure of human cytomegalovirus protease.人类巨细胞病毒蛋白酶的三维结构
Nature. 1996 Sep 19;383(6597):279-82. doi: 10.1038/383279a0.
5
Activity in monomers of human cytomegalovirus protease.人巨细胞病毒蛋白酶单体的活性
Biochem Biophys Res Commun. 1999 Jun 7;259(2):370-3. doi: 10.1006/bbrc.1999.0743.
6
Characterization of human cytomegalovirus protease dimerization by analytical centrifugation.
Biochemistry. 1996 Dec 3;35(48):15601-10. doi: 10.1021/bi961719f.
7
Active human cytomegalovirus protease is a dimer.活性人巨细胞病毒蛋白酶是一种二聚体。
J Biol Chem. 1996 Mar 29;271(13):7445-9. doi: 10.1074/jbc.271.13.7445.
8
Site-directed mutagenesis probing the catalytic role of arginines 165 and 166 of human cytomegalovirus protease.定点诱变探究人巨细胞病毒蛋白酶中精氨酸165和166的催化作用。
Biochemistry. 1998 Apr 28;37(17):5923-9. doi: 10.1021/bi9726077.
9
Characterization of the monomer-dimer equilibrium of human cytomegalovirus protease by kinetic methods.用人巨细胞病毒蛋白酶单体 - 二聚体平衡的动力学方法进行表征。
Biochemistry. 2004 Jan 20;43(2):316-22. doi: 10.1021/bi035170d.
10
A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease.人巨细胞病毒蛋白酶晶体结构揭示的一种新的丝氨酸蛋白酶折叠。
Nature. 1996 Sep 19;383(6597):272-5. doi: 10.1038/383272a0.

引用本文的文献

1
Kinetics of Bovine leukemia virus aspartic protease reveals its dimerization and conformational change.牛白血病病毒天冬氨酸蛋白酶的动力学研究揭示了其二聚化和构象变化。
PLoS One. 2022 Jul 22;17(7):e0271671. doi: 10.1371/journal.pone.0271671. eCollection 2022.
2
Current and potential treatments for ubiquitous but neglected herpesvirus infections.常见但被忽视的疱疹病毒感染的现有及潜在治疗方法。
Chem Rev. 2014 Nov 26;114(22):11382-412. doi: 10.1021/cr500255e. Epub 2014 Oct 2.
3
Cytomegalovirus capsid protease: biological substrates are cleaved more efficiently by full-length enzyme (pUL80a) than by the catalytic domain (assemblin).
巨细胞病毒衣壳蛋白酶:全长酶 (pUL80a) 比催化结构域 (assemblin) 更有效地切割生物底物。
J Virol. 2011 Apr;85(7):3526-34. doi: 10.1128/JVI.02663-10. Epub 2011 Jan 26.
4
Inhibition of a viral enzyme by a small-molecule dimer disruptor.小分子二聚体干扰剂对病毒酶的抑制作用。
Nat Chem Biol. 2009 Sep;5(9):640-6. doi: 10.1038/nchembio.192. Epub 2009 Jul 26.
5
Viral protease inhibitors.病毒蛋白酶抑制剂
Handb Exp Pharmacol. 2009;189(189):85-110. doi: 10.1007/978-3-540-79086-0_4.
6
Enzymatic activities of human cytomegalovirus maturational protease assemblin and its precursor (pPR, pUL80a) are comparable: [corrected] maximal activity of pPR requires self-interaction through its scaffolding domain.人类巨细胞病毒成熟蛋白酶装配素及其前体(pPR,pUL80a)的酶活性相当:[已修正]pPR的最大活性需要通过其支架结构域进行自我相互作用。
J Virol. 2007 Apr;81(8):4091-103. doi: 10.1128/JVI.02821-06. Epub 2007 Feb 7.
7
Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format.用于高通量筛选人巨细胞病毒蛋白酶抑制剂的新型酵母细胞检测法。
Antimicrob Agents Chemother. 2006 Feb;50(2):565-71. doi: 10.1128/AAC.50.2.565-571.2006.
8
Cleavage of human cytomegalovirus protease pUL80a at internal and cryptic sites is not essential but enhances infectivity.人巨细胞病毒蛋白酶pUL80a在内部和隐蔽位点的切割并非必需,但可增强感染性。
J Virol. 2005 Oct;79(20):12961-8. doi: 10.1128/JVI.79.20.12961-12968.2005.
9
Molecular architecture and assembly mechanism of Drosophila tripeptidyl peptidase II.果蝇三肽基肽酶II的分子结构与组装机制
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10135-40. doi: 10.1073/pnas.0504569102. Epub 2005 Jul 8.
10
Herpesvirus protease inhibition by dimer disruption.通过破坏二聚体抑制疱疹病毒蛋白酶
J Virol. 2004 Jun;78(12):6657-65. doi: 10.1128/JVI.78.12.6657-6665.2004.